Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

UCSB physicists create microscopic device to help biologists understand protein folding

Physicists at UC Santa Barbara have created a microscopic device to assist biologists in making very fast molecular measurements that aid the understanding of protein folding. This development may help elucidate biological processes associated with diseases such as Alzheimer's and Parkinson's. Since proteins in the body perform different functions according to their shape, the folding process is considered a key area of study.

18 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

18 Jun 2010

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

18 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

Alzheimer's disease may damage brain

Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.

17 Jun 2010

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

QR Pharma, Inc. (QR) and Massachusetts General Hospital announced today a new collaborative research agreement to work on a treatment for Parkinson's disease (PD).

17 Jun 2010

Many Huntington's disease patients suffer from weight loss, sleeping problems

An aggregating protein causes many of the symptoms of Huntington's disease, an incurable and frequently fatal brain disorder. Mosaic winner Ahmad Aziz discovered that the abnormal protein also aggregates in the hypothalamus, the part of the brain that regulates the autonomic nervous system and the endocrine system.

16 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Sapient Discovery, LLC., a structure-guided drug discovery company, announced today that it has entered into a research collaboration agreement with the Helicon Therapeutics, Inc., a San Diego based pharmaceutical company. Under the terms of the agreement, Sapient Discovery will apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of interest to Helicon Therapeutics, Inc.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

15 Jun 2010

Project ideas needed from worldwide Alzheimer Disease research community

On the 9 June 2010, 119 participants from industry, academia, and related stakeholder communities in the U.S. and Europe joined Alzforum for a Webinar, "Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD," presented by Alzheimer's Disease Cooperative Study (ADCS) director Paul Aisen, MD.

15 Jun 2010

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

A molecule implicated in Alzheimer's disease interferes with brain cells by making them unable to "recycle" the surface receptors that respond to incoming signals, researchers at UT Southwestern Medical Center have found.

15 Jun 2010

Study: Mentally active lifestyle may protect against memory and learning problems in MS

A new study shows that a mentally active lifestyle may protect against the memory and learning problems that often occur in multiple sclerosis. The study is published in the June 15, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

15 Jun 2010

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

Apple juice can be a useful supplement for calming the declining moods that are part of the normal progression of moderate-to-severe Alzheimer's Disease, according to a study in American Journal of Alzheimer's Disease and Other Dementias, published by SAGE.

15 Jun 2010

O2h signs agreement to provide Senexis with chemistry services to support patent filing

Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.

14 Jun 2010

CAMD releases first combined clinical trial data on neuro-degenerative diseases

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD). This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

Researchers report 4 pillars of preventive medicine for AD

Although effective treatment for Alzheimer's disease has been slow to emerge, there has been substantial progress in identifying AD risk factors and developing treatments that might delay or prevent onset of the disease. In a Special Issue of the Journal of Alzheimer's Disease, "Basics of Alzheimer's Disease Prevention," researchers report on key findings that point towards possible significant interventions.

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Alzheimer's Disease News and Research

Further Reading

UCSB physicists create microscopic device to help biologists understand protein folding

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

Alzheimer's disease may damage brain

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

Many Huntington's disease patients suffer from weight loss, sleeping problems

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Project ideas needed from worldwide Alzheimer Disease research community

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

Study: Mentally active lifestyle may protect against memory and learning problems in MS

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

O2h signs agreement to provide Senexis with chemistry services to support patent filing

CAMD releases first combined clinical trial data on neuro-degenerative diseases

Researchers report 4 pillars of preventive medicine for AD

National MS Society commits over $2.4M to support 7 CCSVI research projects

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News